A Multicenter, Feasibility Study Exploring Self-Administration of Chemotherapy in the Home Environment: The EASE...

Area of Science:

• Oncology
• Hematology
• Patient Care Management

Background:

• Previous research focused on nurse-led home administration of bortezomib for multiple myeloma.
• The impact of patient self-administration of bortezomib has not been extensively studied.

Purpose of the Study:

• To assess the feasibility and impact of subcutaneous bortezomib self-administration by patients.
• To evaluate the efficacy, safety, patient/caregiver satisfaction, and cost-effectiveness of this intervention.

Main Methods:

• Prospective feasibility study involving 34 multiple myeloma patients.
• Assessment of efficacy, safety, patient and caregiver satisfaction via questionnaires.
• Analysis of direct institutional and indirect patient costs.

Main Results:

• 1194 doses of bortezomib were self-administered with minimal impact on treatment efficacy.
• No safety concerns arose from self-administration, with only 8 grade 3+ adverse events.
• High patient satisfaction (99% would choose clinic again), stable caregiver quality of life, and significant cost savings (over $1.8M institutional, $23K patient).

Conclusions:

• Patient self-administration of bortezomib is an effective and safe treatment option.
• The intervention is well-received by patients and caregivers, enhancing satisfaction.
• Bortezomib self-administration presents a cost-effective model for multiple myeloma management.